A novel non-steroidal treatment approach for moderate Atopic dermatitis in a 13-month-old infant using SNEPI: a case report.

IF 3.9
Cheol-Jung Yang, Sin-Hye Park, Daewook Lee, Sin-Hwe Kim, Minha Kim, Je-Hun Lee, So-Jung Kim, Taek-Sung Kim, Kook-Hee An, Eun-Ae Kim, Hae-Jung Oh, Jeong Won Seong
{"title":"A novel non-steroidal treatment approach for moderate Atopic dermatitis in a 13-month-old infant using SNEPI: a case report.","authors":"Cheol-Jung Yang, Sin-Hye Park, Daewook Lee, Sin-Hwe Kim, Minha Kim, Je-Hun Lee, So-Jung Kim, Taek-Sung Kim, Kook-Hee An, Eun-Ae Kim, Hae-Jung Oh, Jeong Won Seong","doi":"10.1080/09546634.2025.2562308","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin condition with increasing prevalence in infancy. Standard treatments rely heavily on topical corticosteroids, but concerns about long-term side effects and limited efficacy in some cases highlight the need for alternative therapeutic strategies.</p><p><strong>Methods: </strong>We present a 13-month-old male with moderate AD refractory to moisturizers and hydrocortisone ointments. Sympathetic Nerve Entrapment Point Injection (SNEPI) was administered bilaterally at the T7 paraspinal level using 1 mL of normal saline once weekly for three sessions. Clinical outcomes were monitored during treatment and over a six-year follow-up period.</p><p><strong>Results: </strong>Pruritus resolved and sleep normalized after the first treatment. By the third session, complete remission of skin lesions was achieved without corticosteroid use, with no recurrence observed during four weeks of follow-up. During a six-year follow-up, the child maintained stable skin with only occasional mild pruritus, suggesting sustained therapeutic benefit.</p><p><strong>Conclusions: </strong>This case demonstrates the potential of SNEPI as a safe, effective, and steroid-free neuromodulatory treatment for pediatric AD, supporting the role of autonomic modulation in inflammatory skin disorders. Further clinical studies are warranted to evaluate the broader applicability of SNEPI in pediatric dermatology.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2562308"},"PeriodicalIF":3.9000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2025.2562308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Atopic dermatitis (AD) is a chronic inflammatory skin condition with increasing prevalence in infancy. Standard treatments rely heavily on topical corticosteroids, but concerns about long-term side effects and limited efficacy in some cases highlight the need for alternative therapeutic strategies.

Methods: We present a 13-month-old male with moderate AD refractory to moisturizers and hydrocortisone ointments. Sympathetic Nerve Entrapment Point Injection (SNEPI) was administered bilaterally at the T7 paraspinal level using 1 mL of normal saline once weekly for three sessions. Clinical outcomes were monitored during treatment and over a six-year follow-up period.

Results: Pruritus resolved and sleep normalized after the first treatment. By the third session, complete remission of skin lesions was achieved without corticosteroid use, with no recurrence observed during four weeks of follow-up. During a six-year follow-up, the child maintained stable skin with only occasional mild pruritus, suggesting sustained therapeutic benefit.

Conclusions: This case demonstrates the potential of SNEPI as a safe, effective, and steroid-free neuromodulatory treatment for pediatric AD, supporting the role of autonomic modulation in inflammatory skin disorders. Further clinical studies are warranted to evaluate the broader applicability of SNEPI in pediatric dermatology.

一种使用SNEPI治疗13个月大婴儿中度特应性皮炎的新型非甾体治疗方法:一例报告。
目的:特应性皮炎(AD)是一种慢性炎症性皮肤疾病,在婴儿中发病率越来越高。标准治疗严重依赖于局部皮质类固醇,但对长期副作用和在某些情况下有限的疗效的担忧突出了替代治疗策略的必要性。方法:我们提出一个13个月大的男性中度AD对保湿剂和氢化可的松软膏难治。交感神经压迫点注射(SNEPI)在T7棘旁水平双侧使用生理盐水1 mL,每周1次,共3次。在治疗期间和六年的随访期间监测临床结果。结果:首次治疗后瘙痒缓解,睡眠恢复正常。到第三期,皮肤病变完全缓解,无需使用皮质类固醇,在四周的随访中没有观察到复发。在6年的随访中,儿童皮肤保持稳定,只有偶尔轻度瘙痒,表明持续的治疗效果。结论:该病例证明了SNEPI作为一种安全、有效、无类固醇的儿童AD神经调节治疗方法的潜力,支持自主神经调节在炎症性皮肤疾病中的作用。需要进一步的临床研究来评估SNEPI在儿童皮肤病学中的广泛适用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信